NEW YORK (GenomeWeb News) – Genomind, a firm developing genetic tests focused on psychiatry and neurology, announced today the closing of a $5 million financing round.
Claritas Capital led the round, which will be used to grow Chalfont, Penn.-based Genomind and its product portfolio. Its lead test is the Genecept Assay, a saliva-based test that assesses ten genes to help clinicians make treatment decisions for patients with depression and other psychiatric disorders. With today's funding, the company plans to increase adoption of the test, Genomind CEO Ronald Dozoretz said.
In November, Genomind also announced it acquired the exclusive rights from Emory University to commercialize blood-based protein biomarkers for assessing mild cognitive impairment and Alzheimer's disease.